Zhejiang Cheng Yi Pharmaceutical Co (SHSE:603811) NonCurrent Deferred Liabilities: ¥0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603811 Zhejiang Cheng Yi Pharmaceutical Co Ltd SHSE:603811
86 GF Score
Price ¥7.21
GF Value ¥7.64
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Zhejiang Cheng Yi Pharmaceutical Co NonCurrent Deferred Liabilities?

Zhejiang Cheng Yi Pharmaceutical Co SHSE:603811 -1.50% 86 NonCurrent Deferred Liabilities is ¥0.0 Mil as of Jun. 2026. GuruFocus rates SHSE:603811 with a GF Score™ of 86/100 and a GF Value™ of ¥7.64 (Fairly Valued). The stock has 3 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Zhejiang Cheng Yi Pharmaceutical Co's non-current deferred liabilities for the quarter that ended in Jun. 2026 was ¥0.0 Mil.

Zhejiang Cheng Yi Pharmaceutical Co NonCurrent Deferred Liabilities Related Terms

Zhejiang Cheng Yi Pharmaceutical Co NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Zhejiang Cheng Yi Pharmaceutical Co's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhejiang Cheng Yi Pharmaceutical Co NonCurrent Deferred Liabilities Chart

Zhejiang Cheng Yi Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Zhejiang Cheng Yi Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SHSE:603811
86GF Score
Zhejiang Cheng Yi Pharmaceutical Co Ltd SHSE:603811
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of ¥0.0 Mil mean?
Zhejiang Cheng Yi Pharmaceutical Co (SHSE:603811) has a NonCurrent Deferred Liabilities of ¥0.0 Mil as of Jun. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Zhejiang Cheng Yi Pharmaceutical Co and its competitors.
Is Zhejiang Cheng Yi Pharmaceutical Co's NonCurrent Deferred Liabilities too high?
Zhejiang Cheng Yi Pharmaceutical Co's current NonCurrent Deferred Liabilities is ¥0.0 Mil. Overall, Zhejiang Cheng Yi Pharmaceutical Co has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Cheng Yi Pharmaceutical Co's NonCurrent Deferred Liabilities compare to ZTS?
Zhejiang Cheng Yi Pharmaceutical Co's NonCurrent Deferred Liabilities of ¥0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Drug Manufacturers company?
A good NonCurrent Deferred Liabilities depends on the Drug Manufacturers industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Zhejiang Cheng Yi Pharmaceutical Co and its competitors. Zhejiang Cheng Yi Pharmaceutical Co's current NonCurrent Deferred Liabilities is ¥0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Cheng Yi Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Cheng Yi Pharmaceutical Co (SHSE:603811) is currently considered Fairly Valued. The stock's GF Value™ is ¥7.64, compared to a current price of ¥7.21 — trading 5.6% below its estimated fair value. The current NonCurrent Deferred Liabilities is ¥0.0 Mil. Zhejiang Cheng Yi Pharmaceutical Co's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Zhejiang Cheng Yi Pharmaceutical Co (SHSE:603811), the current NonCurrent Deferred Liabilities is ¥0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zhejiang Cheng Yi Pharmaceutical Co (SHSE:603811) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang Cheng Yi Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥7.21 is trading 5.6% below its estimated GF Value™ of ¥7.64. GuruFocus considers Zhejiang Cheng Yi Pharmaceutical Co to be Fairly Valued.

Key valuation signals for SHSE:603811:

  • NonCurrent Deferred Liabilities: ¥0.0 Mil
  • GF Value™: ¥7.64 vs. price of ¥7.21 (5.6% below fair value)
  • GF Score™: 86/100 with 3 warning signs

No single metric tells the full story. See the SHSE:603811 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zhejiang Cheng Yi Pharmaceutical Co Business Description

Address Lane 988, Shenhong Road, 7th Floor, No. 9, Building 20, Fuli Yuedu, Minhang District, Shanghai, CHN, 201100
Zhejiang Cheng Yi Pharmaceutical Co Ltd is a pharmaceutical company that produces capsules, injections, tablets, APIs, and pharmaceutical intermediates in China. Its main products include glucosamine hydrochloride raw materials and preparations, torasemide injection and capsules, Gastrodin raw materials, ribavirin and purine raw materials, and so on.
86GF Score

Get the complete analysis for SHSE:603811

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥7.21
Price
¥7.64
GF Value